{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The highest dose at which ≤ 33% of subjects have a dose limiting toxicity (DLT) in a cohort of up to 6 subjects.","groups":[{"description":"The Dose Escalation Phase included a total of 18 subjects in 9 different dosage cohorts: 20 mg QD, 40 mg QD, 80 mg QD, 160 mg QD, 300 mg QD, 600 mg QD, 1000 mg QD, 500 mg BID, and 1300 mg QD.","id":"OG000","title":"Dose Escalation Phase"}],"paramType":"NUMBER","populationDescription":"In order to determine the MTD, a total of 18 subjects were enrolled in the dose escalation phase of the study in 9 dosage cohorts. All subjects receiving at least 75% of planned doses of SRA737 within Cycle 1 and those subjects receiving less than these planned doses of SRA737 due to DLT were considered evaluable for dose review decisions.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 days) in the Dose Escalation Phase","title":"Maximum Tolerated Dose of SRA737","type":"PRIMARY","unitOfMeasure":"mg QD"}